Pharmacotherapy in the Era of Pandemics: Latest Advances and Prospects

Dear Colleagues, 

Medications should not be considered as static elements or isolated from the physiological phenomena of the human body or their interaction with other medications. They are dynamic tools, with effects that can be modified by multiple factors and whose use must be balanced to optimize the therapeutic objectives sought and to avoid unwanted effects. Additionally, their use should also be supervised by specialists.

These are difficult times, times in which the emergence of pathogens potentially capable of spreading to produce pandemics makes the sound of war drums, in which medicines are invaluable and essential allies against those tiny beings that strive to circumvent the mechanisms of action of our squalid arsenal. In essence, drugs can act both at the level of prevention and treatment. The sudden emergence of unknown pathogens capable of producing diseases that we are not capable of curing or even alleviating at the time we detect them undoubtedly forces us to investigate to promote the development of these types of drugs. Leaving the research for the moment in which the urgency of the unknown invades us, as we have seen with COVID, is very expensive in terms of health. Additionally, investment in One Health should be mandatory, because most of the consequences that we observe in human health are derived from inaction at other levels.

In this Special Issue, all the papers will present research on drugs used in emerging infectious or non-infectious diseases, their mechanisms of action, interaction with other drugs or repositioning of drugs not used for their intended use in these diseases.

Dr. Antonio Gutiérrez-Pizarraya
Dr. Dorota Kopciuch
Dr. Anna Paczkowska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.